ArticleNature communications2018
A macromolecular approach to eradicate multidrug resistant bacterial infections while mitigating drug resistance onset.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 329 citations in OpenAlex.
- Nanomaterial strategies for antibiotic-resistant infections: Mechanistic frameworks, rational design, and clinical translation.Materials today. Bio · 2026Review
- Membrane-Focused Strategies AgainstAntibiotics (Basel, Switzerland) · 2026Review
- Bioinspired, Guanidinium, and Indole Modified Poly(glycidyl ether)s as Highly Efficient Vectors for Polyplex-Mediated Gene Delivery.Macromolecular rapid communications · 2026Article
- Biguanide-functionalized peptide mimics effectively combat drug-resistant ESKAPE pathogens and meningitis.Nature communications · 2025Article
- Poly(imidazolium ester) antibiotic forms intracellular polymer-nucleic acid biomolecular condensates and fight drug-resistant bacteria.Nature communications · 2025Article
- Synergistic Antimicrobial Activity of BrSPR20-P1 Peptide and Silver Nanoparticles Against Pathogenic Bacteria.International journal of molecular sciences · 2025Article
- Carbene formation as a mechanism for efficient intracellular uptake of cationic antimicrobial carbon acid polymers.Nature communications · 2025Article
- Bioinspired Cationic Antimicrobial Polymers.Angewandte Chemie (International ed. in English) · 2025Review
- Polyacrylamide-Based Antimicrobial Copolymers to Replace or Rescue Antibiotics.ACS central science · 2025Article
- On-demand imidazolidinyl urea-based tissue-like, self-healable, and antibacterial hydrogels for infectious wound care.Bioactive materials · 2025Article
- Eugenol nanoparticle as a therapeutic agent against Pseudomonas infection in mice.Pathogens and disease · 2025Article
- Dexamethasone loaded DNA scavenger nanogel for systemic lupus erythematosus treatment.Bioactive materials · 2025Article
- Advances in nanotechnology for the therapy of bacterial pneumonia.Frontiers in cellular and infection microbiology · 2025Review
- Design, Synthesis, and Activity Evaluation of C-23-Modified 5-ACS medicinal chemistry letters · 2024Article
- Cholic-Acid Derived, Guanidine-Functionalized Polymers as Broad-Spectrum Antimicrobial Agents.ACS omega · 2024Article
- Development of Low-Toxicity Antimicrobial Polycarbonates Bearing Lysine Residues.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Fluoroamphiphilic polymers exterminate multidrug-resistant Gram-negative ESKAPE pathogens while attenuating drug resistance.Science advances · 2024Article
- AI-guided few-shot inverse design of HDP-mimicking polymers against drug-resistant bacteria.Nature communications · 2024Article
- Unveiling the potent activity of a synthetic ion transporter against multidrug-resistant Gram-positive bacteria and biofilms.RSC medicinal chemistry · 2024Article
- A dual-targeting antifungal is effective against multidrug-resistant human fungal pathogens.Nature microbiology · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 3 countries.
Funding
Abstract
Polymyxins remain the last line treatment for multidrug-resistant (MDR) infections. As polymyxins resistance emerges, there is an urgent need to develop effective antimicrobial agents capable of mitigating MDR. Here, we report biodegradable guanidinium-functionalized polycarbonates with a distinctive mechanism that does not induce drug resistance. Unlike conventional antibiotics, repeated use of the polymers does not lead to drug resistance. Transcriptomic analysis of bacteria further supports development of resistance to antibiotics but not to the macromolecules after 30 treatments. Importantly, high in vivo treatment efficacy of the macromolecules is achieved in MDR A. baumannii-, E. coli-, K. pneumoniae-, methicillin-resistant S. aureus-, cecal ligation and puncture-induced polymicrobial peritonitis, and P. aeruginosa lung infection mouse models while remaining non-toxic (e.g., therapeutic index-ED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.